BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24471811)

  • 21. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis].
    Yamamoto T; Tsuji S
    Brain Nerve; 2010 Aug; 62(8):838-51. PubMed ID: 20714032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization.
    Saiki M; Sakai K; Saiki S; Kitagawa Y; Nakanishi M; Hirose G
    J Autoimmun; 2005 May; 24(3):203-8. PubMed ID: 15848042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
    Fu P; He L; Tang N; Nie Q; Li Z
    J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration.
    Carpenter EL; Vance BA; Klein RS; Voloschin A; Dalmau J; Vonderheide RH
    J Neuroimmunol; 2008 Jan; 193(1-2):173-82. PubMed ID: 18053582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a man with esophageal adenocarcinoma.
    Xia K; Saltzman JR; Carr-Locke DL
    MedGenMed; 2003 Aug; 5(3):18. PubMed ID: 14600654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paraneoplastic cerebellar degeneration caused by ovarian clear-cell carcinoma.
    Negishi Y; Sakai K; Noguchi Y; Iwasaki N; Kawai N
    J Obstet Gynaecol Res; 2014 Feb; 40(2):614-7. PubMed ID: 24148073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
    Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
    Storstein A; Krossnes BK; Vedeler CA
    Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
    Yshii L; Bost C; Liblau R
    Front Immunol; 2020; 11():991. PubMed ID: 32655545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Slow evolution of cerebellar degeneration and chorea in a man with anti-Yo antibodies.
    Krolak-Salmon P; Androdias G; Meyronet D; Aguera M; Honnorat J; Vighetto A
    Eur J Neurol; 2006 Mar; 13(3):307-8. PubMed ID: 16618353
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.
    Tanriverdi O; Meydan N; Barutca S; Ozsan N; Gurel D; Veral A
    Jpn J Clin Oncol; 2013 May; 43(5):563-8. PubMed ID: 23475537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration.
    Do LD; Gupton SL; Tanji K; Bastien J; Brugière S; Couté Y; Quadrio I; Rogemond V; Fabien N; Desestret V; Honnorat J
    Cerebellum; 2019 Apr; 18(2):245-254. PubMed ID: 30350014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.
    Huemer F; Melchardt T; Tränkenschuh W; Neureiter D; Moser G; Magnes T; Weiss L; Schlattau A; Hufnagl C; Ricken G; Höftberger R; Greil R; Egle A
    BMC Cancer; 2015 Dec; 15():996. PubMed ID: 26694863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration.
    de Graaff E; Maat P; Hulsenboom E; van den Berg R; van den Bent M; Demmers J; Lugtenburg PJ; Hoogenraad CC; Sillevis Smitt P
    Ann Neurol; 2012 Jun; 71(6):815-24. PubMed ID: 22447725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Paraneoplastic cerebellar degeneration].
    Chabriat H; Chen QM; Poisson M; Delattre JY
    Rev Neurol (Paris); 1994; 150(2):105-14. PubMed ID: 7863150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
    Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
    Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome antibodies in paraneoplastic cerebellar degeneration.
    Storstein A; Knudsen A; Vedeler CA
    J Neuroimmunol; 2005 Aug; 165(1-2):172-8. PubMed ID: 15964637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study.
    Brieva-Ruíz L; Diaz-Hurtado M; Matias-Guiu X; Márquez-Medina D; Tarragona J; Graus F
    Clin Neurol Neurosurg; 2008 Dec; 110(10):1044-6. PubMed ID: 18701208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhombencephalitis associated with isolated Zic4-antibodies in Paraneoplastic cerebellar degeneration: a case report.
    Loehrer PA; Timmermann L; Pehl A; Bien CI; Pfestroff A; Pedrosa DJ
    BMC Neurol; 2020 May; 20(1):208. PubMed ID: 32450842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VGCC antibody-positive paraneoplastic cerebellar degeneration presenting with positioning vertigo.
    Ogawa E; Sakakibara R; Kawashima K; Yoshida T; Kishi M; Tateno F; Kataoka M; Kawashima T; Yamamoto M
    Neurol Sci; 2011 Dec; 32(6):1209-12. PubMed ID: 21678073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.